Plain-English translation of NCT06087458 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Age-Related Macular Degeneration research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing , a new medication delivered as a single injection into the eye, for people with geographic atrophy—an advanced form of dry age-related macular degeneration (AMD). Researchers want to find the safest dose and see whether this treatment can slow or stop vision loss in people with this condition. The trial is divided into two parts: the first part tests different dose levels to find the right amount, and the second part compares the treatment eye to the untreated eye to measure how well it works.
Geographic atrophy causes progressive vision loss and currently has no cure. This medication is being tested because researchers hope it may help slow the deterioration of sight in people with this advanced eye condition.
You would receive a single injection of the medication into one eye at the beginning of the study. Your other eye would not receive treatment, allowing doctors to compare how the treated eye responds over time. You would then return for scheduled eye exams and imaging tests to monitor your vision and check for any side effects. The trial carefully tracks how safe the treatment is and whether it helps preserve your sight.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States